Premium
Prognosis of new‐onset heart failure outpatients and collagen biomarkers
Author(s) -
Sanchis Laura,
Andrea Rut,
Falces Carles,
Llopis Jaume,
MoralesRuiz Manuel,
LópezSobrino Teresa,
PérezVilla Félix,
Sitges Marta,
Sabate Manel,
Brugada Josep
Publication year - 2015
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/eci.12479
Subject(s) - heart failure , medicine , ejection fraction , cardiology , prospective cohort study , diastolic heart failure
Background Prognosis of heart failure patients has been defined in hospital‐based or retrospective studies. This study aimed to characterize prognosis of outpatients with new‐onset preserved or reduced ejection fraction heart failure; to explore the role of collagen turnover biomarkers ( MMP 2, MMP 9, TIMP 1) in predicting prognosis; and to analyse their relationship with echocardiographic parameters and final diagnosis. Methods This is an observational, prospective, longitudinal study. Outpatients with new‐onset heart failure symptoms referred to a one‐stop clinic were included. Echocardiography and biomarkers plasma levels determination were performed at the inclusion. A prospective follow‐up was conducted to report cardiovascular events. The discriminant analysis was applied to identify the parameters related to cardiovascular outcomes. Results A total of 172 patients (75 ± 9 years) were included, 67% with heart failure (64% preserved and 36% with reduced ejection fraction). During follow‐up (median 34·5 months), 32·6% had at least one cardiovascular event and 9·9% died. Heart failure groups showed no differences in cardiovascular outcomes with a higher rate of events than nonheart failure patients. MMP 2 and TIMP 1 were correlated with diastolic dysfunction (Rho 0·349 and 0·294, P < 0·001). In the discriminant analysis, the combination of biomarkers with clinical, biochemical and echocardiographic parameters was useful to predict cardiovascular outcomes ( AUC ROC 0·806, Wilks lambda 0·7688, P < 0·001). Conclusions Prognosis of outpatients with new‐onset heart failure symptoms is comparable between heart failure with preserved or reduced subgroups. The addition of biomarkers specially MMP 2 and high sensitive troponin I to other clinical, biochemical and echocardiographic variables can predict cardiovascular prognosis at the time of diagnosis.